Literature DB >> 15161853

Immune responses to retinal self-antigens in CD25(+)CD4(+) regulatory T-cell-depleted mice.

Masaru Takeuchi1, Hiroshi Keino, Takeshi Kezuka, Masahiko Usui, Osamu Taguchi.   

Abstract

PURPOSE: Prior work has shown that autoimmune uveoretinitis develops spontaneously in CD25(+)CD4(+) regulatory T-cell-depleted mice (Tr-depleted mice). In this study, the generation of autoantibodies and autoreactive T-cells specific to retinal antigens was examined in Tr-depleted mice with uveoretinitis, and the pathogenic and immunogenic abilities of the autoreactive T cells were evaluated.
METHODS: Tr-depletion was achieved in (C57BL/6 x A/J) F1 (B6A) mice by thymectomy on day 3 of life followed by intraperitoneal injection of an anti-CD25 mAb. At 6 months of age, autoantibodies to the retina were evaluated by indirect immunofluorescence, and total IgG2a levels in sera were assessed by ELISA. The pathogenic abilities of the splenic T cells were examined by adoptive transfer to syngeneic nu/nu mice, and the proliferation responses and the secretion of granulocyte-macrophage-colony-stimulating factor (GM-CSF), IFN-gamma, and IL-10 on stimulation by retinal self-antigens was also evaluated.
RESULTS: Autoantibodies to the retinal photoreceptor cell layer were detected in Tr-depleted mice, and the titers correlated well with the grades of inflammatory lesions. The splenic CD4(+) T cells of Tr-depleted mice induced uveoretinitis in the recipients by adoptive transfer and exhibited proliferative responses and secretion of IFN-gamma, but not of IL-10, by in vitro stimulation with S-Ag and interphotoreceptor retinoid-binding protein (IRBP). Moreover, the total IgG2a level in serum was markedly and significantly augmented in Tr-depleted mice.
CONCLUSIONS: The results suggest that in Tr-depleted mice in which uveoretinitis develops, S-Ag and IRBP-specific T cells are spontaneously sensitized and shifted to a Th1-phenotype. These sensitized T cells may account for the development of autoimmune uveoretinitis in Tr-depleted mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161853     DOI: 10.1167/iovs.02-1030

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.

Authors:  H Keino; M Takeuchi; Y Usui; T Hattori; N Yamakawa; T Kezuka; J-I Sakai; M Usui
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

2.  A denileukin diftitox (Ontak) associated retinopathy?

Authors:  J B Ruddle; C A Harper; D Hönemann; J F Seymour; H M Prince
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

Review 3.  Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Authors:  I L Huibregtse; A U van Lent; S J H van Deventer
Journal:  Gut       Date:  2006-10-17       Impact factor: 23.059

4.  Role of CD25+ dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis.

Authors:  Dongchun Liang; Aijun Zuo; Hui Shao; Willi K Born; Rebecca L O'Brien; Henry J Kaplan; Deming Sun
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

5.  Effect of CD4(+)CD25(+) regulatory T cells in the development of anterior chamber-associated immune deviation.

Authors:  Shu-Xing Ji; Xiao-Lei Yin; Pei-Zeng Yang
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

6.  Roles of CD4+CD25+ T cells in the development of experimental murine allergic conjunctivitis.

Authors:  Atsuki Fukushima; Tomoko Yamaguchi; Tamaki Sumi; Ken Fukuda; Naoki Kumagai; Teruo Nishida; Masaru Takeuchi; Osamu Taguchi; Hisayuki Ueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.535

Review 7.  Lymphopenia-induced proliferation in aire-deficient mice helps to explain their autoimmunity and differences from human patients.

Authors:  Kai Kisand; Pärt Peterson; Martti Laan
Journal:  Front Immunol       Date:  2014-02-13       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.